November 16, 2017 10:05 AM ESTUpdated December 18, 12:14 AM

Let the jousting begin: Which top biopharma companies are looking to make a splash at ASH?

John Carroll

Editor & Founder

Anyone who follows oncology knows the field has attracted so much attention and research money that it sparks a continual eruption of biopharma news as …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Let the jousting begin: Which top biopharma companies are looking to make a splash at ASH?

John Carroll

Editor & Founder

Sign up to read this article for free.

GSK to pay $1.2B upfront to snag Boston Pharma’s mid-stage MASH hope

Novo turns to Septerna for oral obesity medicines in deal worth up to $2.2B

Advocacy groups and experts call for decade-long ban on germline editing

TIGIT graveyard expands as GSK drops late-stage asset with iTeos

CRISPR patent spat revived by federal appeals court ruling

Some generics, biosimilar drugmakers say they can withstand tariff impact

Let the joust­ing be­gin: Which top bio­phar­ma com­pa­nies are look­ing to make a splash at ASH?

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

GSK to pay $1.2B up­front to snag Boston Phar­ma’s mid-stage MASH hope

No­vo turns to Septer­na for oral obe­si­ty med­i­cines in deal worth up to $2.2B

Ad­vo­ca­cy groups and ex­perts call for decade-long ban on germline edit­ing

TIG­IT grave­yard ex­pands as GSK drops late-stage as­set with iTeos

CRISPR patent spat re­vived by fed­er­al ap­peals court rul­ing

Some gener­ics, biosim­i­lar drug­mak­ers say they can with­stand tar­iff im­pact

Let the jousting begin: Which top biopharma companies are looking to make a splash at ASH?

GSK to pay $1.2B upfront to snag Boston Pharma’s mid-stage MASH hope

Novo turns to Septerna for oral obesity medicines in deal worth up to $2.2B

Advocacy groups and experts call for decade-long ban on germline editing

TIGIT graveyard expands as GSK drops late-stage asset with iTeos

CRISPR patent spat revived by federal appeals court ruling

Some generics, biosimilar drugmakers say they can withstand tariff impact